CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team
1. CorMedix acquires Melinta Therapeutics, expanding its product portfolio significantly. 2. Revised 2025 revenue guidance now estimates $325-$350 million combined. 3. Acquisition expected to be accretive to EPS with significant annual synergies. 4. REZZAYO™ Phase III trial could boost future revenues significantly. 5. New leadership team aims for strategic integration and growth.